<DOC>
	<DOCNO>NCT01456312</DOCNO>
	<brief_summary>Primary objective : Compare Pegasys RGT overall response rate ( i.e. , HBeAg seroconversion rate ) Pegasys mono historical response rate week 72 ( 48 week treatment 24 week follow ) Secondary objective : - The change HBsAg titer - The rate combine HBeAg seroconversion HBV DNA &lt; 300 copies/mL ⅲ . The rate serum HBV DNA &lt; 300 copies/mL - The rate ALT normalization ⅴ . The rate HBsAg loss ⅵ . The rate serum HBV DNA &lt; 10,000 copies/mL</brief_summary>
	<brief_title>HBsAg Related Response Guided Therapy</brief_title>
	<detailed_description>After 12w treatment Pegasys , depend result quantitative HBsAg test , Patients allocate one three group . - HBsAg &gt; 20,000 : study termination - Group A :1,500 &lt; HBsAg≤ 20,000 - Group B : .HBsAg ≤ 1500 At week 48 , accord HbeAg seroconversion , patient allocate one two sub-groups ( A-1 , A-2 , B-1 , B-2 ) Patients see evaluation treatment week 4,8,12,24,36,48 . Post-treatment assessment perform 4,12 24 week off-treatment phase assessment primary main secondary endpoint study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Positive HBsAg 6 month , positive HBeAg , detectable HBV DNA ( patient must &gt; 100,000 copies/ml measure PCR ) antiHBs negative 3 . Elevated serum ALT &gt; 2ULN ≤ 10 × ULN determine two abnormal value take ≥ 14 day apart six month first dose study drug least one determination obtain ≤ 35 day prior first dose . 1 . Patients must receive antiviral therapy chronic hepatitis B . Patients expect need systemic antiviral therapy provide study time participation study also exclude . Exception : patient le 6 month treatment NA ( Nucleos ( ) ide analog ) 1 year washout period systemic antiviral therapy negative result NA resistance test baseline exclude . 2 . Positive test screen HAV IgM Ab , HCVRNA HCV Ab , HDV Ab HIV Ab . 3 . Diagnosed hepatic cellular carcinoma 4 . Any evidence decompensated liver disease ( Childs BC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Peginterferon alfa 2a</keyword>
	<keyword>Entecavir</keyword>
	<keyword>Response Guided Therapy</keyword>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>